Editas Medicine (EDIT) Enterprise Value (2015 - 2025)
Editas Medicine (EDIT) reported Enterprise Value of -$146.6 million for Q4 2025, up 45.67% year-over-year from -$100.7 million in Q4 2024, and up 11.47% on a QoQ basis from -$165.6 million in Q3 2025.
Editas Medicine (EDIT) has 11 years of Enterprise Value data on file, last reported at -$146.6 million in Q4 2025.
- Quarterly Enterprise Value rose 45.67% year-over-year to -$146.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$146.6 million (up 45.67% YoY) and the FY2025 annual result came in at -$146.6 million, up 45.67% from the prior year.
- Enterprise Value climbed to -$146.6 million in Q4 2025 per EDIT's latest filing, from -$165.6 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$146.6 million in Q4 2025 and bottomed at -$625.3 million in Q1 2021.
- The 5-year median for Enterprise Value is -$333.7 million (2022), against an average of -$362.2 million.
- The widest annual swing landed in 2021, when Enterprise Value tumbled 50.69%; it then jumped 45.67% in 2025.
- Tracing EDIT's Enterprise Value over 5 years: stood at -$499.8 million in 2021, then jumped by 31.12% to -$344.3 million in 2022, then advanced by 6.15% to -$323.1 million in 2023, then climbed by 16.46% to -$269.9 million in 2024, then jumped by 45.67% to -$146.6 million in 2025.
- Per Business Quant, the three latest EDIT Enterprise Value figures stand at -$146.6 million (Q4 2025), -$165.6 million (Q3 2025), and -$178.5 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.32 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | -32.30 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -286.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | -61.46 Mn |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.77 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | -7.25 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -8.75 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -3.01 Bn |
| 10 | Editas Medicine | 338.62 Mn | 338.62 Mn | - | -146.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -146.65 Mn |
| Sep 30, 2025 | -165.65 Mn |
| Jun 30, 2025 | -178.50 Mn |
| Mar 31, 2025 | -220.96 Mn |
| Dec 31, 2024 | -269.91 Mn |
| Sep 30, 2024 | -265.09 Mn |
| Jun 30, 2024 | -279.11 Mn |
| Mar 31, 2024 | -296.17 Mn |
| Dec 31, 2023 | -323.11 Mn |
| Sep 30, 2023 | -349.62 Mn |
| Jun 30, 2023 | -431.97 Mn |
| Mar 31, 2023 | -318.44 Mn |
| Dec 31, 2022 | -344.27 Mn |
| Sep 30, 2022 | -419.62 Mn |
| Jun 30, 2022 | -452.56 Mn |
| Mar 31, 2022 | -488.36 Mn |
| Dec 31, 2021 | -499.85 Mn |
| Sep 30, 2021 | -557.84 Mn |
| Jun 30, 2021 | -610.55 Mn |
| Mar 31, 2021 | -625.33 Mn |
| Dec 31, 2020 | -402.11 Mn |
| Sep 30, 2020 | -495.31 Mn |
| Jun 30, 2020 | -598.72 Mn |
| Mar 31, 2020 | -414.99 Mn |
| Dec 31, 2019 | -457.14 Mn |
| Sep 30, 2019 | -332.62 Mn |
| Jun 30, 2019 | -317.93 Mn |
| Mar 31, 2019 | -342.07 Mn |
| Dec 31, 2018 | -368.96 Mn |
| Sep 30, 2018 | -337.49 Mn |
| Jun 30, 2018 | -344.08 Mn |
| Mar 31, 2018 | -358.82 Mn |
| Dec 31, 2017 | -329.14 Mn |
| Sep 30, 2017 | -295.69 Mn |
| Jun 30, 2017 | -324.80 Mn |
| Mar 31, 2017 | -351.55 Mn |
| Dec 31, 2016 | -185.32 Mn |
| Sep 30, 2016 | -199.87 Mn |
| Jun 30, 2016 | -217.65 Mn |
| Mar 31, 2016 | -229.20 Mn |
| Dec 31, 2015 | -84.15 Mn |
| Sep 30, 2015 | -155.30 Mn |
| Jun 30, 2015 | -47.04 Mn |
| Mar 31, 2015 | -5.17 Mn |